Last reviewed · How we verify
Antispasmodic
At a glance
| Generic name | Antispasmodic |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of IV Lidocaine on Duodenal Peristalsis and Sedation in ERCP (PHASE4)
- Sublingual Atropine Bioequivalence by Route of Administration (SABER) (PHASE1)
- Outcome of Patients With Malignant Gastric Outlet Obstruction Undergoing Endoscopic Ultrasound-guided Gastroenterostomy or Enteral Metal Stenting
- Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (NA)
- Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome. (NA)
- Radial accEss Crossover for PErcutaneous Coronary Procedures And ouTcome: the REPEAT Study
- Radial Extracorporeal Shock Wave Therapy for Chronic Non-specific Low Back Pain (NA)
- DIstal vs Proximal Radial Artery Access for Cath (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antispasmodic CI brief — competitive landscape report
- Antispasmodic updates RSS · CI watch RSS
- Assiut University portfolio CI